Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRONTSE:GUDNYSE:RIVNASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$1.86-2.6%$1.93$1.60▼$2.54$717.37M1.041.35 million shs1.30 million shsGUDKnight TherapeuticsC$5.85+0.2%C$5.87C$5.09▼C$6.45C$591.73M0.568,358 shs26,608 shsRIVRiverNorth Opportunities Fund$12.02+0.4%$11.75$10.11▼$12.96N/AN/A81,457 shs54,949 shsTLRYTilray Brands$0.36-6.1%$0.44$0.36▼$2.15$362.34M1.8329.55 million shs43.18 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group0.00%-3.63%-9.27%+3.91%-19.48%GUDKnight Therapeutics0.00%-2.99%+1.56%-5.34%+7.34%RIVRiverNorth Opportunities Fund0.00%+0.04%+1.09%+1.95%+0.33%TLRYTilray Brands0.00%-10.89%-19.46%-44.62%-78.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRONCronos Group0.8467 of 5 stars0.05.00.00.00.60.01.3GUDKnight Therapeutics1.8413 of 5 stars2.80.00.00.03.31.70.6RIVRiverNorth Opportunities FundN/AN/AN/AN/AN/AN/AN/AN/ATLRYTilray Brands1.7643 of 5 stars3.12.00.00.01.90.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 0.00N/AN/AN/AGUDKnight Therapeutics 3.50Strong BuyC$7.1522.22% UpsideRIVRiverNorth Opportunities Fund 0.00N/AN/AN/ATLRYTilray Brands 2.25Hold$1.92432.41% UpsideCurrent Analyst Ratings BreakdownLatest RIV, CRON, GUD, and TLRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025GUDKnight TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetHold ➝ BuyC$6.504/14/2025TLRYTilray BrandsRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/9/2025TLRYTilray BrandsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.003/25/2025GUDKnight TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuyC$6.25 ➝ C$7.45(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$117.61M6.10N/AN/A$2.90 per share0.64GUDKnight TherapeuticsC$348.70M1.70C$1.52 per share3.85C$7.65 per share0.76RIVRiverNorth Opportunities Fund$44.13MN/AN/AN/AN/AN/ATLRYTilray Brands$788.94M0.46N/AN/A$4.14 per share0.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group$41.08M$0.1314.3162.0042.1839.69%-0.07%-0.07%8/6/2025 (Estimated)GUDKnight Therapeutics-C$30.73M-C$0.30N/A∞N/A-8.81%-4.04%0.51%N/ARIVRiverNorth Opportunities FundN/AN/A0.00∞N/AN/AN/AN/AN/ATLRYTilray Brands-$244.98M-$1.05N/AN/AN/A-113.85%-7.40%-6.02%8/4/2025 (Estimated)Latest RIV, CRON, GUD, and TLRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 million4/8/2025Q3 2025TLRYTilray Brands-$0.04-$0.10-$0.06-$0.87$213.38 million$185.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/AGUDKnight TherapeuticsN/AN/AN/AN/AN/ARIVRiverNorth Opportunities Fund$1.5412.81%N/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ALatest RIV, CRON, GUD, and TLRY DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/4/2025RIVRiverNorth Opportunities Fundmonthly$0.127713%6/13/20256/13/20256/30/20254/3/2025RIVRiverNorth Opportunities Fundmonthly$0.127713%6/13/20256/13/20256/30/20255/13/2025RIVRiverNorth Opportunities Fund$0.127712.72%5/15/20255/16/20255/30/20254/9/2025RIVRiverNorth Opportunities Fund$0.127714.71%4/15/20254/16/20254/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A27.8026.75GUDKnight Therapeutics7.523.361.79RIVRiverNorth Opportunities FundN/AN/AN/ATLRYTilray Brands0.122.621.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%GUDKnight Therapeutics12.58%RIVRiverNorth Opportunities FundN/ATLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipCRONCronos Group6.90%GUDKnight Therapeutics45.62%RIVRiverNorth Opportunities FundN/ATLRYTilray Brands0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450385.68 million359.07 millionOptionableGUDKnight Therapeutics725101.15 millionN/ANot OptionableRIVRiverNorth Opportunities FundN/AN/AN/ANot OptionableTLRYTilray Brands2,6501.01 billion1.00 billionOptionableRIV, CRON, GUD, and TLRY HeadlinesRecent News About These CompaniesTilray Brands (NASDAQ:TLRY) Shares Down 3.2% - Should You Sell?June 20 at 1:19 PM | marketbeat.comWhy Tilray Brands, Inc. (TLRY) Dipped More Than Broader Market TodayJune 17, 2025 | zacks.comTensions in Middle East Weigh on TSXJune 17, 2025 | theglobeandmail.comTilray (NASDAQ:TLRY) Shares Down 5.8% - What's Next?June 17, 2025 | marketbeat.com3 Canadian Cannabis Stocks Traders Are Watching Closely This WeekJune 17, 2025 | marijuanastocks.comTilray (NASDAQ:TLRY) Trading 4.5% Higher - Here's WhyJune 16, 2025 | marketbeat.comTilray (NASDAQ:TLRY) Trading Down 1.3% - Here's What HappenedJune 13, 2025 | marketbeat.comTilray (NASDAQ:TLRY) Shares Up 5.3% - What's Next?June 11, 2025 | marketbeat.comHere's why the Tilray Brands stock has crashed, and what's next?June 10, 2025 | invezz.comTilray Brands' Stockholders Approve Reverse Stock Split;Â Company Pauses Implementation as It Evaluates Timing and Stock PriceJune 10, 2025 | globenewswire.comManitoba Harvest and Whole Foods Market Collaborate to Launch New Protein-Packed, Hemp+ Superfood Smoothie BoostersJune 10, 2025 | globenewswire.com660,834 Shares in Tilray Inc (NASDAQ:TLRY) Bought by Millennium Management LLCJune 7, 2025 | marketbeat.comTilray (NASDAQ:TLRY) Shares Up 2.8% - Here's WhyJune 6, 2025 | marketbeat.comMarijuana Stocks To Watch With Strong Market PotentialJune 6, 2025 | marijuanastocks.comTilray (NASDAQ:TLRY) Trading Down 1.2% - What's Next?June 5, 2025 | marketbeat.comAttention Craft Beer Fans! Tilray Beverages Highlights Boldest Brews For SummerJune 5, 2025 | globenewswire.comTilray (NASDAQ:TLRY) Shares Up 2.1% - What's Next?June 4, 2025 | marketbeat.comPromising Cannabis Stocks To Watch Today - June 3rdJune 3, 2025 | marketbeat.comBNP Paribas Financial Markets Reduces Stake in Tilray Inc (NASDAQ:TLRY)June 3, 2025 | marketbeat.comTilray (NASDAQ:TLRY) Shares Down 3.7% - Here's What HappenedJune 2, 2025 | marketbeat.comJune 2025 Watchlist: Best Canadian Cannabis Stocks for GrowthMay 31, 2025 | marijuanastocks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Industrials Stocks Standing Out for Growth and Analyst OptimismBy Nathan Reiff | June 4, 2025View 3 Industrials Stocks Standing Out for Growth and Analyst OptimismQuantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationBy Leo Miller | May 27, 2025View Quantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationAMD Accelerates Stack Development: Share Price to FollowBy Thomas Hughes | June 16, 2025View AMD Accelerates Stack Development: Share Price to FollowTesla: Why Analysts Think It Could Jump Another 47%By Sam Quirke | May 27, 2025View Tesla: Why Analysts Think It Could Jump Another 47%Alphabet Stock Lags—But Waymo May Be Its Hidden DriverBy Gabriel Osorio-Mazilli | May 25, 2025View Alphabet Stock Lags—But Waymo May Be Its Hidden DriverRIV, CRON, GUD, and TLRY Company DescriptionsCronos Group NASDAQ:CRON$1.86 -0.05 (-2.62%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.88 +0.02 (+1.29%) As of 06/20/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Knight Therapeutics TSE:GUDC$5.85 +0.01 (+0.17%) As of 06/20/2025 04:00 PM EasternKnight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.RiverNorth Opportunities Fund NYSE:RIV$12.02 +0.05 (+0.42%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$12.02 0.00 (0.00%) As of 06/20/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RiverNorth Opportunities Fund, Inc. is a close ended equity mutual fund co- launched and co- managed by ALPS Advisors, Inc. and RiverNorth Capital Management, LLC. It invests in the equity markets. The fund seeks to invest in stocks of companies operating across the diversified sectors. RiverNorth Opportunities Fund, Inc. was formed on December 24, 2015 and is domiciled in the United States.Tilray Brands NASDAQ:TLRY$0.36 -0.02 (-6.08%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.37 +0.01 (+2.78%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
